BTX1701 has completely disappeared from investor and external...

BTX1701 has completely disappeared from investor and external presentations this year. The last mention of 1701 I can find is in the investor presentation '13 November 2017'. In that document it outlines the plan for a patient study in Q1 2018. Since then, I can't see it mentioned at all (though it remains on their website)..

Why has this dropped off? Market opportunity wasn't attractive enough? Don't think so. BOT's limited time and resources better spent on developing 1503 and 1204? Maybe. 1801 popped up and became the shiny new toy? Perhaps.

My guess is that they realised doing a deal on 1701, despite offering short term revenue, would compromise 1503 as it moves through Ph2 and Ph3. Imagine licencing 1701 now, it hitting the market mid-next year (right when the 1503 Ph2 data is released). A 1503 suitor wouldn't be thrilled that BTX had licenced out a product using the same IP already (even though it's at the 'mild' end). It would complicate negotiations. My guess is that 1701 reappears (or is integrated) once 1503 is licenced, so they don't devalue our golden goose in the meantime. If this is the case, onwards and upwards, and good management.

Interested to hear other opinions..